\(
\def\WIPO{World Intellectual Property Organisation}
\)
Pharmaceutical Innovation, Competition and Patent Law : A Trilateral Perspective.
2013
G 25 DRE.P
Available at WIPO Library
格式
| 格式 | |
|---|---|
| BibTeX | |
| MARCXML | |
| TextMARC | |
| MARC | |
| DataCite | |
| DublinCore | |
| EndNote | |
| NLM | |
| RefWorks | |
| RIS |
Items
详细记录
Title
Pharmaceutical Innovation, Competition and Patent Law : A Trilateral Perspective.
Author
描述
352 pages ; 25 cm
国际图书编号
9780857932457 Print
9780857932464 eBook
9780857932464 eBook
Alternate Call Number
G 25 DRE.P
摘要
Public health, safety and access to reasonably priced medicine are common policy goals of pharmaceutical regulations. As both the context for innovation and competitive structure change, industry actors dynamically challenge the balance between the incentive for protection and the achievement of those policy goals. Considering the arguments from the perspectives of innovation, competition law and patent law, this book explores the difficult question of balancing protection with access, highlighting the difficulties in harmonization and coordination. The contributors to this book, including academics, judges and practitioners from Europe, the US and Japan, explore to what extent patent strategies and life-cycle management practices take advantage of patent laws and health-care regulation and disrupt the necessary balance between incentives for innovation and access to affordable medicine and health care. Addressing fundamental questions in the field of pharmaceutical innovation, this book will appeal to scholars and practitioners in intellectual property, competition law and life sciences regulation, as well as pharmaceutical companies and regulators.
书目等附注
Includes bibliographical references and index.
格式化内容附注
Introduction
Part I: Patent Protection for Pharmaceutical Methods
1. The Patentability of Genetic Diagnostics in US Law and Policy
2. Patentability of Pharmaceutical Innovations: The European Perspective
3. Patentability of Medical Methods in Japan
Part II: Data Exclusivity And Patent Term Extension: Convergence Or Divergence
4. Patent Term Restoration and Non-Patent Exclusivity in the US
5. Clinical Data, Data Exclusivity and Private Investment Protection in Europe
6. Patent Term Extension in Japan: An Academic and Comparative Perspective
7. Recent UK Case Law on Supplementary Protection Certificates
8. Patent Term Extension in Japan: Focusing on the Pacif Capsule Decision
Part III: Balancing Incentives and Competition in Europe
9. Strategic Patenting by the Pharmaceutical Industry: Towards a Concept of Abusive Practices of Protection
10. Anticompetitive Marketing in the Context of Pharmaceutical Switching in Europe
11. AstraZeneca and the EU Sector Inquiry: When Do Patent Filings Violate Competition Law?
Index
Part I: Patent Protection for Pharmaceutical Methods
1. The Patentability of Genetic Diagnostics in US Law and Policy
2. Patentability of Pharmaceutical Innovations: The European Perspective
3. Patentability of Medical Methods in Japan
Part II: Data Exclusivity And Patent Term Extension: Convergence Or Divergence
4. Patent Term Restoration and Non-Patent Exclusivity in the US
5. Clinical Data, Data Exclusivity and Private Investment Protection in Europe
6. Patent Term Extension in Japan: An Academic and Comparative Perspective
7. Recent UK Case Law on Supplementary Protection Certificates
8. Patent Term Extension in Japan: Focusing on the Pacif Capsule Decision
Part III: Balancing Incentives and Competition in Europe
9. Strategic Patenting by the Pharmaceutical Industry: Towards a Concept of Abusive Practices of Protection
10. Anticompetitive Marketing in the Context of Pharmaceutical Switching in Europe
11. AstraZeneca and the EU Sector Inquiry: When Do Patent Filings Violate Competition Law?
Index
连续资源
Published
Cheltenham, UK : Edward Elgar, 2013.
语言
eng